期刊文献+

乙型肝炎病毒核心抗原的原核表达及纯化 被引量:2

Prokaryotic Expression and Purification of Hepatitis B Virus Core Antigen
原文传递
导出
摘要 目的原核表达乙型肝炎病毒核心抗原(HBcAg),纯化HBcAg病毒样颗粒(Virus-like particle,VLP),并对其理化性质进行鉴定。方法根据大肠杆菌密码子偏爱性对HBcAg基因进行密码子优化,全基因合成优化基因,克隆至载体pET-32a(+)中,构建原核表达质粒pET-HBcAg,转化大肠杆菌BL21(DE3),IPTG诱导表达。重组蛋白经盐析和层析纯化后,经SDS-PAGE、Western blot、电镜观察、等电点分析、高效液相色谱(HPLC)分析和N-末端氨基酸测序等进行鉴定。结果重组表达质粒经酶切和测序鉴定证明构建正确;表达的重组蛋白相对分子质量约为21 000,为可溶性表达,表达量占菌体总蛋白的21.6%;纯化后其纯度可达99.4%,具有良好的反应原性,VLP形成良好,结构均一,等电点在pH 6.0~6.9之间,HPLC分析形成T3和T4两种不同结构,N-末端序列正确,无氨基酸降解。结论已成功构建了HBcAg原核表达质粒,并获得了高纯度的HBcAgVLP,为进一步研究HBcAg VLP的生物学特性奠定了基础。 Objective To express hepatitis B virus core antigen(HBcAg) in prokaryotic cells,purify the virus-like particles(VLPs) and analyze their physic-chemical property.Methods The codon of HBcAg was optimized according to the E.coli-perference,then synthesized and cloned into vector pET-32a(+).The constructed prokaryotic expression vector pET-HBcAg was transformed to E.coli BL21(DE3) for expression under induction of IPTG.The expressed recombinant protein was purified by salting out and chromatography,and identified by SDS-PAGE,Western blot,electron microscopy,isoelectric point analysis,HPLC and N-terminal amino acid sequencing.Results Restriction analysis and sequencing proved that recombinant expression vector was constructed correctly.The expressed recombinant protein in a soluble form,with a relative molecular mass of about 21 000,contained 21.6% of total somatic protein.The purified recombinant protein reached a purity of 99.4% and showed good antigenicity.VLPs with uniform structure were formed,of which the isoelectric point ranged from pH 6.0 to pH 6.9.HPLC showed T3 and T4 structures and correct sequence at N-terminus of HBcAg but no amino acid degradation.Conclusion The prokaryotic expression vector for HBcAg was successfully constructed,and highly purified HBcAg VLPs were obtained,which laid a foundation of further study on biological characters of HBcAg VLPs.
出处 《中国生物制品学杂志》 CAS CSCD 2011年第10期1121-1125,共5页 Chinese Journal of Biologicals
基金 艾滋病和病毒性肝炎等重大传染病防治专项(2008ZX10002-002)
关键词 肝炎核心抗原 乙型 病毒样颗粒 基因优化 原核细胞 基因表达 纯化 Hepatitis core antigen B Virus-like particles(VLPs) Gene optimization Prokaryotic cells Gene expression Purification
  • 相关文献

参考文献13

  • 1WHO Media centre, Hepatitis B [ OL ]. http://www.who.int / me- diacentre / factsheets / fs204 / en/.
  • 2Huang Z, Santi L, LePore K, et al. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice [J]. Vaccine, 2006,24 (14): 2506-2513.
  • 3Sominskaya I, Skrastina D, Dislers A, et al. Construction and im- munological evaluation of muhivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes [J]. Clin Vac- cine Immunol, 2010 , 17 (6): 1027-1033.
  • 4Lau GK, Liang R, Lee CK, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B sur- face antibody-positive [J]. J Infect Dis, 1998,178 (6): 1585-1591.
  • 5夏其昌,曾嵘.蛋白质化学与蛋白质组学[M].北京:科学出版社,2006:285-286.
  • 6Billaud JN, Peterson D, Lee BO, et al. Advantages to the use of rodent hepadnavims core proteins as vaccine platforms [J]. Vac- cine, 2007,25 (9): 1593-1606.
  • 7Nystrom J, Chen A, Frelin L, et al. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lympho- cytes [J]. J Infect Dis, 2010,201 (12): 1867-1879.
  • 8Aguilar JC, Lobaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen [J]. Immunol Cell Biol, 2004 ,82 (5): 539-546.
  • 9Safety study of HBV DNA vaccine to treat patients with chronic hepatitis B infection [OL]. (2008-11-20)[2010-09-14]. http: // clinicaltrials.gov / ct2 / show / NCT00277576.
  • 10McKelvie ND, Stratford R, Wu T, et al. Expression of heterolo- gous antigens in Salmonella typhimurium vaccine vectors using the in vivo-inducible, SPI-2 promoter, ssaG [J]. Vaccine, 2004, 22 (25-26) : 3243-3255.

同被引文献23

  • 1WHO Media centre. Hepatitis B lOLl. (2012-07-xx)[2012-08- 15] http://www.who.int/mediac-entre/ factsheets/fs204/en /.
  • 2Buster EH, Van Erpecum K J, Schalm SW, et al. Treatment of chronic hepatitis B virus infection-Dutch national guidelines [J]. Neth J Med, 2008, 66 (7) : 292-306.
  • 3Buster EH, Schalm SW, Janssen HL. Pegintefferon for the treatment of chronic hepatitis B in the era of nucleos (t)ide analogues [J]. Best Pract Res Clin Gastroenterol, 2008, 22 (6): 1093-1108.
  • 4Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B [J ]. Gut, 2012, 61 (Suppl 1 ): i18-i24.
  • 5Pumpens P, Grens E. HBV core particles as a carrier for B cell/ T cell epitopes [J]. Intervirology, 2001, 44(2-3): 98-114.
  • 6Rehermann B. Immune responses in hepatitis B virus infection [J]. Semin Liver Dis, 2003, 23(1 ): 21-38.
  • 7Gesner ML, Heeke DS, Martins E, et al. A novel therapeutic HBV vaccine induces potent surface- and core-specific immunoge- nicity in mice rhesus macaques [J]. FASEB J, 2008, 22(Suppl) : 859-470.
  • 8Riedl P, Wieland A, Lamberth K, et al. Elimination of immunod- ominant epitopes from muhispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential [J]. J Immunol, 2009, 183 (1): 370-380.
  • 9Wang XJ, Gu K, Xiong QY, et al. A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK [J]. Vaccine, 2009, 27 (52): 7377-7384.
  • 10Aguilar JC, Lohaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Thl response against hepatitis B surface antigen [J]. Immunol Cell Biol, 2004, 82 (5): 539-546.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部